AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10705939 — intervention group
Group type: COMPARATOR
Intervention: Duration of symptoms, type of gamma‐camera or radiopharmaceutical agent used.
Number of subjects: 220
Study 9493655 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (400 mg)
Number of subjects: 7
Study 9493655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7810174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupanine (40.26 mumol)
Number of subjects: 11
Study 7810174 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-hydroxylupanine (37.83 mumol)
Number of subjects: 11
Study 7810174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupanine and 13-hydroxylupanine
Number of subjects: 11
Study 7810174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin seed
Number of subjects: 11
Study 3392126 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (16 IU/day)
Number of subjects: 0
Study 3392126 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (32 IU/day)
Number of subjects: 0
Study 3392126 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (control)
Number of subjects: 0
Study 29635864 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting efficacy regarding EVD
Number of subjects: 447
Study 29635864 — intervention group
Group type: COMPARATOR
Intervention: Emphasizing threat
Number of subjects: 447
Study 28185995 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step mutual help group linkage intervention (individual meeting with a volunteer in jail and post-release support)
Number of subjects: 0
Study 28185995 — intervention group
Group type: COMPARATOR
Intervention: Control condition (providing schedules for local 12-step meetings)
Number of subjects: 0
Study 26271331 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site coaching intervention focused on SCC; duration: 4-6 weeks; modified to peer-to-peer coaching and strengthened training.
Number of subjects: 0
Study 26271331 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intervention implemented in three additional facilities; peer-to-peer coaching and enhanced leadership engagement.
Number of subjects: 0
Study 22925046 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based alcohol assessment and personalized feedback (intervention)
Number of subjects: 1789
Study 22925046 — intervention group
Group type: COMPARATOR
Intervention: Screening alone (control)
Number of subjects: 1789
Study 20882293 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement jumps at 50° knee angle
Number of subjects: 10
Study 20882293 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement jumps at 70° knee angle
Number of subjects: 10
Study 20882293 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement jumps at 90° knee angle
Number of subjects: 10
Study 20882293 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional effort at 25%
Number of subjects: 10
Study 20882293 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional effort at 100%
Number of subjects: 10
Study 20882293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-maximal jumps
Number of subjects: 10
Study 19882857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet autoblood irradiation (UVABI)
Number of subjects: 0
Study 19882857 — intervention group
Group type: COMPARATOR
Intervention: Standard complex therapy without UVABI
Number of subjects: 0
Study 16546539 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0% chlorhexidine
Number of subjects: 15123
Study 16546539 — intervention group
Group type: COMPARATOR
Intervention: Soap and water
Number of subjects: 15123
Study 16546539 — intervention group
Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 15123
Study 14510038 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecommunications case management
Number of subjects: 213
Study 14510038 — intervention group
Group type: COMPARATOR
Intervention: In-person case management
Number of subjects: 213
Study 14510038 — intervention group
Group type: COMPARATOR
Intervention: Limited case management services from primary drug counselors
Number of subjects: 213
Study 14510038 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 213
Study 14510038 — intervention group
Group type: EXPERIMENTAL
Intervention: Other drug use
Number of subjects: 213
Study 11112029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 57
Study 11112029 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 57
Study 9339804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 microg/ml), 5 drops three times a day for 10 days
Number of subjects: 40
Study 9339804 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin sulfate (5 mg/ml), 5 drops three times a day for 10 days
Number of subjects: 40
Study 9339804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Gentamicin sulfate (both groups)
Number of subjects: 40
Study 8244604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmed K2 system
Number of subjects: 20
Study 8244604 — intervention group
Group type: COMPARATOR
Intervention: Douglas bag method
Number of subjects: 20
Study 2412037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg, b.i.d. for 2 weeks, then doubled)
Number of subjects: 331
Study 2412037 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg, b.i.d. for 2 weeks, then doubled)
Number of subjects: 331
Study 2412037 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 331
Study 2412037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 331
Study 2412037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin and Propranolol
Number of subjects: 331
Study 30160787 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tofacitinib ointment applied twice daily
Number of subjects: 16
Study 30160787 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ruxolitinib ointment
Number of subjects: 16
Study 30160787 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol dipropionate 0.005% ointment
Number of subjects: 16
Study 30160787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 16
Study 30160787 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized hair regrowth
Number of subjects: 16
Study 27344195 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone counseling intervention for smoking cessation
Number of subjects: 1837
Study 23900641 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of L‐3,4‐dihydroxyphenylalanine (L‐DOPA)
Number of subjects: 201
Study 23900641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 23351674 — intervention group
Group type: EXPERIMENTAL
Intervention: KO Palu NightWatch activities
Number of subjects: 519000
Study 21418609 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer
Number of subjects: 30
Study 21418609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 30
Study 21418609 — intervention group
Group type: COMPARATOR
Intervention: IPAQ
Number of subjects: 30
Study 18376656 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-pressure irrigation system
Number of subjects: 0
Study 16860613 — intervention group
Group type: EXPERIMENTAL
Intervention: AGA II IgA
Number of subjects: 92
Study 16860613 — intervention group
Group type: EXPERIMENTAL
Intervention: AGA II IgG
Number of subjects: 92
Study 16860613 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet after 6 months
Number of subjects: 92
Study 16860613 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet after 1 year
Number of subjects: 92
Study 16860613 — intervention group
Group type: COMPARATOR
Intervention: AGA II compared to conventional AGA
Number of subjects: 92
Study 16860613 — intervention group
Group type: COMPARATOR
Intervention: AGA II compared to antitissue transglutaminase antibodies
Number of subjects: 92
Study 12673141 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose supplementation
Number of subjects: 8
Study 12673141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no glucose supplementation)
Number of subjects: 8
Study 12673141 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline (no exercise)
Number of subjects: 8
Study 10870980 — intervention group
Group type: EXPERIMENTAL
Intervention: SK and F 107647 (1, 10, 100, 500, and 1000 μg/kg as single 15-minute iv infusion)
Number of subjects: 0
Study 10870980 — intervention group
Group type: EXPERIMENTAL
Intervention: SK and F 107647 (0.001, 0.01, 0.1 and 1 μg/kg as 2-hour iv infusions once daily for 10 days)
Number of subjects: 0
Study 10164045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-sharing
Number of subjects: 0
Study 10164045 — intervention group
Group type: COMPARATOR
Intervention: Health insurance coverage
Number of subjects: 0
Study 1900978 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 150 mg twice per day for 3 months
Number of subjects: 43
Study 1900978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 6797513 — intervention group
Group type: EXPERIMENTAL
Intervention: Emission computed tomography (emission CT)
Number of subjects: 242
Study 6797513 — intervention group
Group type: COMPARATOR
Intervention: Planar gamma‐camera imaging
Number of subjects: 242
Study 6797513 — intervention group
Group type: COMPARATOR
Intervention: Transmission (x‐ray) CT
Number of subjects: 242
Study 31851388 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially isolated older adults
Number of subjects: 2015
Study 31851388 — intervention group
Group type: COMPARATOR
Intervention: Not socially isolated older adults
Number of subjects: 2015
Study 31200092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 31200092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28403972 — intervention group
Group type: EXPERIMENTAL
Intervention: 7mmHg with AirSeal® system
Number of subjects: 60
Study 28403972 — intervention group
Group type: COMPARATOR
Intervention: 15mmHg standard insufflator
Number of subjects: 60
Study 25450717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 8 mg
Number of subjects: 51
Study 25450717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 25 mg
Number of subjects: 51
Study 25450717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 40 mg
Number of subjects: 51
Study 25450717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 120 mg
Number of subjects: 51
Study 25450717 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg
Number of subjects: 51
Study 23939326 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VRG)
Number of subjects: 60
Study 23939326 — intervention group
Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 60
Study 20678825 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person professional interpreter services
Number of subjects: 447
Study 20678825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interpreter services)
Number of subjects: 447
Study 19476428 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 2180
Study 19476428 — intervention group
Group type: COMPARATOR
Intervention: Menactra
Number of subjects: 2180
Study 17383011 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 403
Study 17383011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 14754626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cane length of 0.92 m
Number of subjects: 15
Study 14754626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cane length of 1.22 m
Number of subjects: 15
Study 14754626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cane length of 1.37 m
Number of subjects: 15
Study 14754626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cane length of 1.67 m
Number of subjects: 15
Study 14754626 — intervention group
Group type: EXPERIMENTAL
Intervention: Block height
Number of subjects: 15
Study 11431134 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation
Number of subjects: 0
Study 11431134 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic testosterone replacement
Number of subjects: 0
Study 11431134 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0
Study 9208343 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 70 suspension (10 ml) with cerivastatin (200 micrograms)
Number of subjects: 8
Study 9208343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.i.d. for 4 days) with cerivastatin (200 micrograms)
Number of subjects: 8
Study 9208343 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin (200 micrograms) alone
Number of subjects: 8
Study 7708405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal capsaicin treatment on the ipsilateral side
Number of subjects: 70
Study 7708405 — intervention group
Group type: COMPARATOR
Intervention: Nasal capsaicin treatment on the contralateral side
Number of subjects: 70
Study 7708405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal capsaicin treatment for chronic patients (ipsilateral and contralateral alternately)
Number of subjects: 70
Study 7708405 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ipsilateral vs contralateral treatment
Number of subjects: 70
Study 3616278 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose trimethoprim 400 mg once
Number of subjects: 90
Study 3616278 — intervention group
Group type: COMPARATOR
Intervention: Multi-dose trimethoprim 200 mg twice daily for five days
Number of subjects: 90
Study 29629591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Locking Blade Plate (DLBP)
Number of subjects: 106
Study 26892939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitemporal ECT
Number of subjects: 138
Study 26892939 — intervention group
Group type: COMPARATOR
Intervention: High-dose unilateral ECT
Number of subjects: 138
Study 26892939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 138
Study 25460255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled light (7 am-7 pm lights on, 7 pm-7 am lights off, n=17)
Number of subjects: 34
Study 25460255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim light (lights off whenever the child is asleep, n=17)
Number of subjects: 34
Study 25460255 — intervention group
Group type: COMPARATOR
Intervention: Term infants (control group, n=14)
Number of subjects: 34
Study 23813330 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 7
Study 20299496 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir monotherapy
Number of subjects: 72
Study 20299496 — intervention group
Group type: COMPARATOR
Intervention: triple therapy including lopinavir/ritonavir
Number of subjects: 72
Study 17597398 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day triple therapy
Number of subjects: 282
Study 17597398 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential regimen
Number of subjects: 282
Study 16186262 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback + reminders
Number of subjects: 4138
Study 16186262 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4138
Study 16186262 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback only
Number of subjects: 4138
Study 16186262 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders only
Number of subjects: 4138
Study 12517650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraabdominal irrigation with normal saline (500-1000 mL)
Number of subjects: 196
Study 12517650 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (Control)
Number of subjects: 196
Study 10769584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril at a dose of 10 mg/day
Number of subjects: 0
Study 10769584 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E supplements at a dose of 400 UI/day
Number of subjects: 0
Study 8804873 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (colloidal bismuth subcitrate 480 mg/day plus metronidazole 750 mg/day and tetracycline 1000 mg/day for 4 weeks)
Number of subjects: 45
Study 8804873 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg/day for 8 weeks
Number of subjects: 45
Study 8804873 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 45
Study 8804873 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 45
Study 1617708 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mega U of pro-urokinase
Number of subjects: 62
Study 1617708 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mega U of pro-urokinase
Number of subjects: 62
Study 1617708 — intervention group
Group type: EXPERIMENTAL
Intervention: 500,000 U of urokinase plus 6.5 mega U of pro-urokinase
Number of subjects: 62
Study 1617708 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 62
Study 6496919 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin + 1000 units of purified human antithrombin III (AT III) concentrate
Number of subjects: 20
Study 6496919 — intervention group
Group type: COMPARATOR
Intervention: Heparin only
Number of subjects: 20
Study 30039442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 238
Study 30039442 — intervention group
Group type: COMPARATOR
Intervention: Saccharated ferric oxide (SFO)
Number of subjects: 238
Study 30039442 — intervention group
Group type: COMPARATOR
Intervention: Both groups (FCM and SFO)
Number of subjects: 238
Study 28527204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose LEV (2.5 mg/kg)
Number of subjects: 0
Study 28527204 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose LEV (7.5 mg/kg)
Number of subjects: 0
Study 28527204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26097215 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg every 4 weeks)
Number of subjects: 190
Study 24199969 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong training (twice a week for 10 weeks)
Number of subjects: 34
Study 24199969 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 21891890 — intervention group
Group type: EXPERIMENTAL
Intervention: HA+200 μg drug solution of ALN
Number of subjects: 15
Study 21891890 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite (HA) bone graft material
Number of subjects: 15
Study 19696601 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Acu/Moxa treatment
Number of subjects: 29
Study 19696601 — intervention group
Group type: COMPARATOR
Intervention: Sham/placebo Acu/Moxa
Number of subjects: 29
Study 16754631 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0
Study 16754631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12943880 — intervention group
Group type: EXPERIMENTAL
Intervention: Jo heparin‐coated stent deployment
Number of subjects: 202
Study 12943880 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 202
Study 10781272 — intervention group
Group type: EXPERIMENTAL
Intervention: Episcleral anesthesia
Number of subjects: 66
Study 10781272 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 66
Study 8793794 — intervention group
Group type: COMPARATOR
Intervention: Single-use cellulose dialyzers
Number of subjects: 37
Study 8793794 — intervention group
Group type: EXPERIMENTAL
Intervention: Reuse cellulose dialyzers
Number of subjects: 37
Study 1632658 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day by mouth
Number of subjects: 21
Study 6489428 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 12‐14 mg/kg
Number of subjects: 21
Study 6489428 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 22‐27 mg/kg
Number of subjects: 21
Study 6489428 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen repeated doses every 4 or 8 h for 1 to 3 days
Number of subjects: 21
Study 6489428 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen repeated doses
Number of subjects: 21
Study 6489428 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 21
Study 31581416 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater morning snacking
Number of subjects: 2265
Study 31581416 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater evening snacking
Number of subjects: 2265
Study 31581416 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-day snacking
Number of subjects: 2265
Study 29020483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), applied three times weekly.
Number of subjects: 216
Study 25706661 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute step test (6MST)
Number of subjects: 91
Study 24510352 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical visual distractor
Number of subjects: 0
Study 24510352 — intervention group
Group type: COMPARATOR
Intervention: Horizontal visual distractor
Number of subjects: 0
Study 24510352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-contrast visual distractor
Number of subjects: 0
Study 24510352 — intervention group
Group type: COMPARATOR
Intervention: Low-contrast visual distractor
Number of subjects: 0
Study 22703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Meal Replacement (PMR)
Number of subjects: 144
Study 22703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Meal Replacement with Inulin (PMR + I)
Number of subjects: 144
Study 22703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (INU)
Number of subjects: 144
Study 22703579 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 144
Study 22703579 — intervention group
Group type: COMPARATOR
Intervention: Low Calorie Diet (LCD)
Number of subjects: 144
Study 20713433 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli intake (250 g/day)
Number of subjects: 27
Study 20713433 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 27
Study 17553051 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amorolfine hydrochloride 5% nail lacquer once weekly for 12 months plus terbinafine 250 mg once daily for 3 months (AT group)
Number of subjects: 249